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ABSTRACT 
Cancer cells can develop a strong addiction to discrete molecular regulators, which 
control the aberrant gene expression programs that drive and maintain the cancer 
phenotype. Here, we report the identification of the RNA-binding protein HuR/ELAVL1 
as a central oncogenic driver for malignant peripheral nerve sheath tumours (MPNSTs), 
which are highly aggressive sarcomas that originate from cells of the Schwann cell 
lineage. HuR was found to be highly elevated and bound to a multitude of cancer-
associated transcripts in human MPNST samples. Accordingly, genetic and 
pharmacological inhibition of HuR had potent cytostatic and cytotoxic effects on tumour 
growth, and strongly supressed metastatic capacity in vivo. Importantly, we linked the 
profound tumorigenic function of HuR to its ability to simultaneously regulate multiple 
essential oncogenic pathways in MPNST cells, including the Wnt/b-Catenin, YAP/TAZ, 
Rb-E2F and BET proteins, which converge on key transcriptional networks. Given the 
exceptional dependency of MPNST cells on HuR for survival, proliferation, and 
dissemination, we propose that HuR represents a promising therapeutic target for 
MPNST treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4 
INTRODUCTION 
Malignant peripheral nerve sheath tumours (MPNSTs) are highly aggressive 
sarcomas with a strong metastatic potential, usually to the lung (1). MPNST patients are 
largely refractory to current treatments that include radical surgical resection and/or 
radiation and chemotherapy, and have very poor 5-year survival rates ranging between 
15% and 50% (1). Half of MPNST cases arise in the context of Neurofibromatosis Type 1 
syndrome (NF1), and these tumours are a leading cause of death in NF1 patients. In NF1, 
loss of the NF1 tumour suppressor gene that encodes the Ras GTPase-activating protein 
neurofibromin leads to the development of benign neurofibromas that are located on 
the skin (cutaneous neurofibromas) or can be deep-seated in large peripheral nerves 
(plexiform neurofibromas). Plexiform neurofibromas can transform into MPNSTs, which 
can also occur spontaneously (sporadic MPNSTs) or after radiotherapy. There is general 
acceptance that cells of the Schwann cell lineage are the crucial neoplastic cells in 
MPNST (1,2). 
A number of mutations that drive MPNST pathogenesis have been identified, 
with a surprising degree of overlap in NF1-associated and sporadic forms. These include 
molecular variants of the NF1 tumour suppressor gene that are present in all NF1 
patients, and in a majority of sporadic and radiation-induced MPNSTs (2,3). Other 
ancillary, yet essential, cancer-driving genetic aberrations include loss of genes CDKN2A, 
TP53, RB, PTEN, or the genes encoding the PRC2 components SUZ12 or EED, and 
amplification of PDGFRA, EGFR or MET (4,5). In addition, recent studies have shown that 
activation of multiple signalling pathways that include the PI3K/AKT/mTOR, RAS/RAF-
MEK-ERK, WNT/β-Catenin and HIPPO-YAP/TAZ pathways, and other less ubiquitous 
molecular alterations involving aurora kinases and transcription factors, such as SOX9, 
also contribute to MPNST pathogenesis (1,3,6). 
 Gene dysregulation is a hallmark of cancer cells. Genetic alterations in cancer 
cells invariably lead to a global remodelling of their transcriptome allowing them to 
acquire advanced functional capabilities for survival, proliferation and dissemination. 
MPNSTs have a unique transcriptomic signature that is clearly distinct from normal or 
even neurofibroma-derived primary Schwann cells or tumours (7,8), and that is strongly 
associated with key Schwann cell developmental programs, including control of survival 
and proliferation. Targeting dysregulated gene expression programs in cancers has 
emerged as a promising therapeutic strategy, and there is an intense focus on 
identifying the key molecular regulators that govern these programs (9,10). In particular, 
RNA-binding proteins (RBPs) are increasingly recognised as attractive targets because of 
their ability to regulate the type and abundance of hundreds of transcripts by 
modulating every aspect of their post-transcriptional life – splicing, transport, 
localization, translation, stabilization and decay. Furthermore, each RBP can bind to 
multiple overlapping groups of functionally related RNAs, forming “RNA regulons” that 
control many biological functions (11). 
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 We have previously shown that the ubiquitously expressed RBP HuR/ELAVL1 was 
highly expressed in immature Schwann cells, a stage of development characterized by a 
peak in Schwann cell proliferation and apoptosis. We found that HuR was bound to and 
regulated several key mRNAs, co-ordinately regulating them at the post-transcriptional 
level (12). Subsequently, as immature Schwann cells differentiated, we found that they 
lost expression of HuR, and the production of HuR targets encoding proliferation and 
apoptosis proteins were downregulated. Notably, many of the HuR targets in immature 
Schwann cells become re-expressed in MPNSTs, and the encoded proteins play key roles 
in tumour growth, as shown for SOX9 (8) and BRD4 (13). HuR is frequently upregulated 
in different cancer types (14), leading us to hypothesize that HuR could become re-
expressed in MPNSTs, where it would have a key role in driving the dysregulated 
transcriptomic programs. Here, we present evidence that HuR is potently tumorigenic 
in MPNSTs and that suppressing HuR expression reduces tumour growth and metastasis. 
We propose that the malignant influence of HuR is linked to enhancing multiple key 
oncogenic programs operating in MPNST cells.  
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RESULTS 
HuR is upregulated in human MPNSTs 
To explore the potential role of HuR in Schwann cell cancers, we searched a 
publicly available expression dataset (GEO: GSE41747)(7) and found that HuR/ELAVL1 
mRNA levels were significantly upregulated in MPNSTs, both in patients and in mouse 
samples (Figure 1A, B). Next, we analysed HuR protein abundance by 
immunohistochemistry in a human tissue microarray panel comprising normal nerves 
(n=7), benign neurofibromas (n=76) and MPNSTs (n=109)(15), and similarly, found a 
strong upregulation of HuR protein expression in MPNSTs (Figure 1C). Finally, we 
validated these results by examining HuR protein and mRNA expression in an 
independent cohort of frozen human normal nerves (n=5), neurofibromas (n=12) and 
MPNSTs (n=15), obtained from the Stanmore Musculoskeletal Biobank (UK). We 
confirmed that total HuR protein levels were significantly elevated in the MPNST 
samples (Figure 1D, E). We also examined cytoplasmic HuR levels, since HuR export from 
the nucleus to the cytoplasm is linked to its function as post-transcriptional regulator of 
target mRNAs (16). As shown (Figure 1D, F), cytoplasmic HuR levels were higher in 
MPNST samples. HuR mRNA levels were also higher in these samples (Figure 1G).  
We did not find significant differences in the abundance of HuR mRNA or protein 
when comparing dermal neurofibromas and plexiform neurofibromas from our frozen 
cancer panel (Supplemental Figure 1A), nor were there differences in HuR mRNA levels 
in publicly available datasets (Supplemental Figure 1B, C). Notably, we also did not find 
significant differences in the levels of HuR mRNA or protein when comparing NF1-
derived and sporadic MPNSTs (Supplemental Figure 1D, E).  
The high abundance and cytoplasmic localisation of HuR point to a potentially 
important role in both sporadic and NF1-derived MPNSTs. 
  
RIP-Chip identifies HuR mRNA targets associated with key cancer traits 
To examine the biological significance of the high HuR levels in MPNSTs, we 
analysed HuR-associated mRNAs on a genome-wide scale by ribonucleoprotein (RNP) 
immunoprecipitation (RIP) under conditions that preserve endogenous RNA-protein 
interactions, followed by microarray detection of bound mRNAs (RIP-Chip) (17,18). 
Notably RIP-chip preferentially enriches for the stably–bound subsets of putative mRNA 
targets rather than transient targets that might be detected by RNP crosslinking. This 
favours the identification of targets forming part of functional complexes that lead to 
mRNA target stabilization and increased translation (19).  
RIP analysis was performed using an anti-HuR antibody or control anti-IgG 
antibody and cytoplasmic extracts from human neurofibroma (n=8) and MPNST (n=12) 
tumour samples from the aforementioned frozen cancer panel, and the isolated RNA 
was identified by microarray analysis (Supplemental Figure 2A, B). Background mRNAs 
identified in side-by-side control IP reactions using mouse anti-IgG antibody were 
subtracted to identify bona fide HuR-interacting mRNAs. We found that HuR was 
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specifically bound to 71 and 276 mRNAs in neurofibroma and MPNST samples 
respectively (Figure 2A, Supplemental Table 1 and 2). The large majority of 
neurofibroma targets (60 out of 71; 85%) were also associated with HuR in the MPNST 
samples, whereas 216 HuR-bound transcripts were exclusively expressed in MPNST 
samples (Figure 2A), in line with the high HuR expression in MPNST samples, and 
supporting a role for HuR in malignant Schwann cell tumours. 
To identify molecular pathways associated with HuR-bound transcripts in 
MPNST, we performed gene set enrichment analysis (GSEA) using Molecular Signature 
Database (MSigDB) hallmarks (20). GSEA revealed significant enrichment of signatures 
associated with oncogenic traits that include cell cycle progression, EMT and 
angiogenesis (21), as well as signatures for key oncogenic transcription factors MYC and 
E2F (22,23) (Figure 2B). In addition, key signalling pathways in MPNSTs that include the 
Wnt/β-Catenin, PI3K/AKT/mTOR and RAS pathways (1,2), were also enriched (Figure 
2B–D; Supplemental Table 3). 
Together, these data point to a potentially important biological function for HuR 
in MPNSTs, possibly regulating key signalling pathways that control oncogenic traits in 
these malignant tumours. 
 
HuR promotes MPNST cell growth in vitro and in vivo 
To characterize the functional importance of HuR, we first evaluated its 
abundance in established MPNST cell lines. Using a publicly available expression dataset 
(GEO: GSE14038) (8), we found that HuR mRNA levels were significantly upregulated in 
MPNST cell lines compared to neurofibroma-derived Schwann cells (Supplemental 
Figure 3A). Furthermore, higher HuR mRNA and protein levels were observed in 4 
commonly used MPNST cell lines (ST88-14, 90-8, S462, STS-26T), compared to freshly 
isolated Schwann cells derived from human nerves (Supplemental Figure 3B, C). 
 We then silenced HuR in these 4 MPNST cell lines by lentiviral delivery of two 
distinct HuR-specific short hairpin (sh) RNAs and examined cellular growth. Three of the 
cell lines (ST-8814, 90–8 and S462) were derived from NF1 patients with confirmed loss 
of heterozygosity at the NF1 locus for all 3 cell lines; the 90–8 cell line additionally 
showed a known microdeletion of NF1, whereas the sporadic MPNST line STS–26T had 
no mutations detected in the 60 exons of the NF1 gene. These MPNST cell lines share a 
common gene expression profile distinct from that of normal Schwann cells, although 
they differ in proliferation rates and in expression of cell cycle proteins (24).  Both 
constitutively expressed shRNAs reduced HuR levels efficiently, and suppressed cell 
growth, as shown by measuring ATP levels and by direct cell counts in all 4 cell lines 
(Supplemental Figure 3D–F). Furthermore, HuR silencing significantly reduced the 
clonogenic and anchorage-independent growth capacity of all 4 cell lines (Supplemental 
Figure 4A–C).  
Since the in vitro consequences of HuR perturbation were shared by all MPNST 
cell lines, we selected as representative STS-26T for in vivo validation. STS-26T cells in 
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which HuR levels were normal or reduced by silencing were implanted subcutaneously 
in immunodeficient mice. Subsequent analysis revealed that whereas control cells 
efficiently formed tumours (5/5), tumour formation was completely abolished in HuR-
silenced cells (0/5) (Figure 3A, B).  
 Next, we examined the effects of HuR depletion on the growth of already 
established tumours. To this end, we used a doxycycline-inducible lentiviral shRNA 
system targeting HuR. STS-26T cells expressing pTRIPZ-sh Control (sh iCtrl) or pTRIPZ-sh 
HuR (sh iHuR) were injected subcutaneously in the left and right flanks of 
immunodeficient mice respectively, and tumours were allowed to form for about 20 
days until they were palpable (~100 mm3 average). Mice were randomly assigned to 
standard chow diet or doxycycline diet for a period of 10 days, whereupon mice were 
sacrificed and tumours extracted (Figure 3C). Remarkably, induction of HuR shRNA by 
doxycycline treatment severely blunted tumour growth, and even led to visible tumour 
regression (Figure 3D). Tumour regression was observed in all mice following HuR 
depletion, and on average tumours shrank by 40% (Figure 3E), and weighed significantly 
less than control tumours (Figure 3F). HuR-depleted cells formed smaller tumours, and 
the efficiency of HuR silencing was confirmed in those tumours by Western blotting 
analysis (Supplemental Figure 5A, B). Notably, tumours arising from sh iHuR cells 
without doxycycline treatment were indistinguishable in all parameters from tumours 
arising from sh iCtrl cells with or without doxycycline treatment, supporting the 
efficiency and specificity of the inducible system used.  
 We also documented a marked reduction in the proliferation marker Ki67 and a 
rise in an apoptotic marker, active Caspase-3, in HuR-depleted tumours (Supplemental 
Figure 5C). We validated these results in the panel of cultured MPNST cell lines, where, 
similarly, genetic depletion of HuR in the 4 cell lines potently reduced cell proliferation 
as measured by (1) cell cycle analysis by flow cytometry, which showed a general 
increase in the percentage of cells in the G1 phase and a decrease in cells in the S and 
G2/M phases, consistent with a G1 cell cycle arrest, and (2) BrdU incorporation 
(Supplemental Figure 6A, B). We also found a marked increase in senescence after HuR 
silencing in all 4 cell lines (Supplemental Figure 6C). Detection of Annexin V by flow 
cytometry indicated a trend towards increased apoptosis in all 4 cell lines after HuR 
knockdown when cells were cultured under basal, growth-promoting conditions (10% 
serum). Exposure to cellular stress, such as culture of cells under growth-limiting 
conditions (2% serum) (13), exaggerated this effect and led to a marked increase in 
apoptotic and necrotic cell death after HuR depletion (Supplemental Figure 6D). 
 Together, these data indicate that HuR play an important functional role in 
MPNST cell biology by controlling key features such as survival, proliferation and 
replicative immortality. 
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HuR promotes MPNST metastasis in vivo 
MPNSTs have a high metastatic potential, and up to 50% of patients develop 
metastatic disease, usually to the lung, further worsening 5-year survival rates of 
patients (1,25). Yet, metastasis is one of the least understood aspects of MPNSTs. Given 
the profound antitumoral effects of HuR in MPNST cells, and the identification of EMT 
signature as one of the top enriched categories of HuR targets from GSEA analysis 
(Figure 2B, C), we decided to examine whether HuR could be important for MPNST 
metastasis, using a surrogate model of lung metastasis. Briefly, this model measures the 
ability of cells injected in the lateral tail vein of immunodeficient mice to survive in 
circulation, arrest at a distant organ, extravasate, adapt to growth in the foreign 
microenvironments of a distant tissue, and grow into metastatic lesions, recapitulating 
many of the essential late steps in metastasis (26). 
We silenced HuR constitutively in STS-26T cells, an MPNST cell line which exhibits 
metastatic tropism to the lung (27), injected them in the tail vein, and examined 
metastatic colonization of the lung 4 weeks later by histology (Figure 4A). Remarkably, 
very few metastatic lesions were observed in HuR-depleted cells in contrast to control 
cells, which formed numerous and large metastatic foci (Figure 4B, C). Next, we used 
our inducible lentiviral silencing system to examine the effect on HuR silencing on the 
colonization step of the metastatic process, i.e. the survival of the cells in these foreign 
microenvironments during the metastatic process, and the reactivation of their 
proliferation programs to form overt metastatic lesions. We injected STS-26T cells 
expressing pTRIPZ-sh Control (sh iCtr) or pTRIPZ-sh HuR (sh iHuR) in the tail vein, and 
allowed them to begin to form metastases for 2 weeks. Mice were randomly assigned 
to standard chow or doxycycline-containing diet for 4 weeks, whereupon mice were 
sacrificed and lungs extracted for histological analysis (Figure 4D). Induction of HuR 
shRNA by doxycycline treatment blocked the conversion of these micrometastases into 
the macroscopic neoplastic growth seen in the control cells with or without doxycycline 
treatment and in sh iHuR cells without doxycycline treatment (Figure 4D–F). 
 Together, these data support a key role for HuR in MPNST metastasis, potentially 
controlling key aspects of the metastatic process, from the survival of the cells in the 
bloodstream to their colonization and proliferation within distant organs. 
 
HuR overexpression in Schwann cells is not sufficient to trigger oncogenic 
transformation or dissemination 
 Since HuR is expressed at notably higher levels in MPNST compared to Schwann 
cells (Figure 1 and Supplemental Figure 3A–C), we next examined whether elevating HuR 
levels in human Schwann cells was sufficient elicit to cell transformation and 
dissemination.  
 We ectopically expressed HA-tagged HuR using a doxycycline-inducible lentiviral 
system (28) in immortalized normal human Schwann cells (iHSCl2) (Supplemental 
Figure 7A), and found that this led to a small but significant increase in cell growth, as 
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shown by measuring ATP levels and by direct cell counts, and increased the clonogenic 
and anchorage-independent growth capacity (Supplemental Figure 7B). However, no 
major effect was observed in tumour formation in vivo using mouse xenograft models 
(Supplemental Figure 7C, D). We also did not observe any major effect on tumour 
formation after ectopic expression of HuR in immortalized plexiform neurofibroma-
derived human Schwann cells (ipNF SC). These data suggest that while HuR 
overexpression promotes proliferation in Schwann cells in culture, it is not sufficient to 
induce Schwann cell-derived tumors in mice. 
Similarly, we examined metastatic properties using tail vein injections of control 
or HuR-overexpressing normal and plexiform neurofibroma-derived human Schwann 
cell lines. We did not find any metastatic nodules in the controls of either cell line. 
Unexpectedly, we found the presence of small micrometastases in HuR-overexpressing 
normal Schwann cell lines (1 out of 4) and plexiform human Schwann cell lines (3 out of 
4) (Supplemental Figure 7E), although these were far fewer and smaller than after 
injection of STS-26T MPNST cell line (Figure 4).  
Taken together, HuR overexpression in normal or plexiform neurofibroma 
Schwann cells was not sufficient to trigger oncogenic transformation but modestly 
increased their metastatic capacity. 
 
Pharmacological inhibition of HuR reduces MPNST growth and metastasis 
Our results demonstrate that elevated HuR levels in MPNST cells are required for 
cell growth and metastasis. We next ascertained whether the inhibition of HuR could be 
exploited as a therapeutic strategy using small molecule HuR inhibitors.  
Pharmacological inhibition of HuR with MS-444, which inhibits HuR 
homodimerization to prevent the binding of 3ʹUTR AU-rich elements (29), pyrvinium 
pamoate (PP), an FDA-approved anthelminthic drug that blocks HuR nucleocytoplasmic 
translocation (30), and tanshinone mimic 6N (TM-6N), which inhibits HuR-RNA complex 
formation (31), each strongly reduced MPNST cell growth in culture, in ST88-14 and STS-
26T cells (Figure 5A, B), similar to what we found through the genetic inhibition of HuR 
(Supplemental Figures 3 and 4). 
 Importantly, intra-peritoneal injection with MS-444 (25 mg/kg body weight; 
treatment every 48h for 10 days) of nude mice bearing already established tumours 
(formed 20 days after xenograft transplant of STS-26T cells in flanks) severely blunted 
tumour growth, and even led to tumour regression in some cases. In addition, MS-444-
treated tumours weighed significantly less than control tumours (Figure 5C–E). 
Remarkably, MS-444 treatment of nude mice (intra-peritoneal injection every 48h for 2 
weeks; 25 mg/kg body weight) with established micrometastases that had formed for 2 
weeks after intravenous injection of STS-26T cells, also reduced the conversion of these 
micrometastases into the macroscopic neoplastic growth, and smaller metastatic areas 
were measured in MS-444-treated mice than in vehicle-treated mice (Figure 5F–H). 
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 Our results show that pharmacological inhibition of HuR reduces MPNST growth 
and metastasis, thus highlighting the relevance of HuR as a potential therapeutical 
target for MPNST. 
  
HuR regulates key oncogenic transcriptional programs 
Next, we sought to define the mechanisms by which HuR exerts such profound 
effects on MPNST cells. We silenced HuR expression using lentiviral vectors expressing 
constitutive shRNA directed at HuR in the ST88-14 cell line, and performed RNA-
sequencing profiling. We identified distinct transcriptomic profiles between the control 
and HuR-depleted cells (Figure 6A), and differential expression analysis revealed that a 
notable proportion of the transcriptome in MPNST cells changed significantly. There 
were similar numbers of significantly upregulated and downregulated transcripts 
exhibiting >2-fold changes (1563 and 1627 respectively) (Figure 6B, Supplemental Table 
4).  
GSEA analysis revealed an inhibition of several tumorigenic pathways in MPNST 
cells by HuR silencing, including the YAP/TAZ, Wnt/b-Catenin, PI3K/AKT/mTOR and RAS 
pathways, in addition to signatures for the key oncogenic transcription factors MYC and 
E2F (Figure 6C, Supplemental Table 5 and 6). There was also significant overlap between 
the signature sets we identified by this RNA-Seq analysis and the RIP-chip analysis for 
putative HuR mRNA targets (Figure 2B). These results strongly suggested that HuR could 
be affecting MPNST cells by directly regulating these pathways, several of which have 
already been established to play key roles in MPNST tumorigenesis (6,7,13,32-34). We 
thus set out to examine the importance of HuR for these pathways. 
We first focused on the YAP/TAZ pathway. In an elegant study, it was recently 
shown that human MPNSTs exhibit elevated HIPPO-TAZ/YAP expression, and 
hyperactivation of YAP/TAZ in Schwann cells activated an oncogenic program with 
development of MPNSTs (6). GSEA analysis of RNA-Seq data showed that HuR silencing 
in MPNST cells led to a strong suppression of a YAP-conserved signature (35) as well as 
a functionally validated YAP-activated signature (36) (Figure 7A,B). Notably, GSEA also 
showed a strong negative correlation of genes regulated by YAP/TAZ hyperactivation in 
Schwann cells (6) and genes regulated by HuR silencing in ST88-14 MPNST cells 
(Supplemental Figure 8A), suggesting that HuR could be responsible for regulating 
expression of YAP/TAZ pathway components.  
 To test this hypothesis, we examined whether HuR associated with mRNAs 
encoding key protein components of the YAP/TAZ pathway by performing RIP followed 
by reverse transcription and quantitative PCR analysis (RIP-qPCR) in MPNSTs. To avoid 
possible confounding effects of cell type heterogeneity in tumour samples, we used 
MPNST cell lines instead. We found that there was a strong enrichment of YAP1 mRNA, 
encoding YAP1, and TEAD1 and TEAD2 mRNAs, encoding TEAD1 and TEAD2, two 
transcriptional partners of YAP1, in HuR RIP samples (Figure 7C). Notably, HuR depletion 
led to a striking reduction in the levels of these proteins in both the NF1-derived ST88-
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14 cell line (Figure 7D), and the sporadic cell line STS-26T (Supplemental Figure 8B). 
Suppressing the YAP/TAZ pathway by HuR silencing reduced the mRNA levels of 
downstream YAP/TAZ target genes in both cell lines (Figure 7E; Supplemental Figure 8C). 
Interestingly, although we did not find that TAZ or TEAD4 mRNAs were direct targets of 
HuR, HuR depletion led to a strong reduction in their expression levels, likely due to an 
indirect effect on their transcription, mRNA stability or translation. 
Our results indicate that HuR can regulate expression of key YAP/TAZ pathway 
components in MPNST cells, which could lead to the aberrant elevated HIPPO-TAZ/YAP 
expression seen in mouse and human tumour tissue samples and the hyperactivation of 
this essential oncogenic pathway for MPNST pathogenesis. 
 
HuR regulates key cell cycle genes in MPNST via a RB-E2F axis 
The RAS-MEK-ERK and PI3K-AKT-mTOR are two other major signalling pathways 
that are upregulated in MPNSTs and have important roles in MPNST pathogenesis (1,2). 
GSEA analysis revealed that many components of these pathways were significantly 
downregulated by HuR silencing, including activation of receptor tyrosine kinases such 
as PDGF (Supplemental Figure 9A, B). Along the same lines, GSEA also showed a strong 
positive correlation among genes regulated by the MEK inhibitor PD0325901 in the 
MPNST cell line 90-8TL (13) and genes regulated by HuR silencing in ST88-14 MPNST 
cells (Supplemental Figure 9C). In addition, several signatures of downstream effectors 
of these pathways, including the RB and E2F transcription factors, were inhibited by HuR 
silencing (Figure 8A, B). These effectors are frequently dysregulated in cancer and play 
an important role in cell cycle regulation (22). 
To examine the specific function of HuR in controlling these tumorigenic 
pathways, we examined whether HuR was bound to and regulated expression of 
different components of these pathways (Figure 8C). By RIP-qPCR analysis, we found 
that HuR was bound to CCND1, CCND2, CDK2, CDK6, p27, E2F1, E2F2 and E2F3 mRNAs 
(Figure 8D). In both the ST88-14 and STS-26T cell lines, we found that silencing HuR 
strongly reduced the levels of several proteins encoded by these mRNAs, accordingly to 
the role of HuR in promoting mRNA stability and translation (Figure 8E, Supplemental 
Figure 9D). However, in specific cases, HuR can also inhibit protein translation (16), as 
described for P27 (37). Here, similarly, we found that HuR depletion led to an increase 
in P27 protein level. P21 protein levels were also induced, not as a direct target of HuR, 
but possibly as one of the key proteins increasing in abundance during cell senescence.  
Collectively, our results suggest that HuR may play a direct role in driving cell 
cycle progression via E2F transcription factors in MPNST cells by acting at several levels: 
(1) by enhancing the expression of specific cyclins and CDKs to promote phosphorylation 
of RB1 to release E2F transcription factors (TFs), (2) by repressing production of P27, an 
inhibitor of CDKs, and (3) by directly regulating the levels of E2F TFs. 
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HuR activates a key Wnt/b-Catenin oncogenic program in MPNST 
Using the Sleeping Beauty forward genetic screen, signalling through the 
canonical Wnt/b-Catenin pathway was recently identified as a key genetic driver of 
MPNST tumorigenesis (33,34). Canonical Wnt pathway is activated after Wnt 
stimulation leading to an inhibition in degradation of β-Catenin, which then enters the 
nucleus and binds to a member of the lymphoid-enhancing factor 1/T-cell factor 
(LEF1/TCF) and other transcriptional cofactors including BCL9 and Pygopus to regulate 
the expression of target genes involved in diverse cellular processes (38). We found that 
HuR silencing led to a downregulation of MYC, SOX9 and AURKA/B mRNAs 
(Supplemental Table 4), which have previously been identified as downstream targets 
of the Wnt/b-Catenin pathway in different cell systems (39-41). Here, we confirmed that 
these genes were also downstream target genes in MPNST cells by silencing b-Catenin 
using specific shRNAs in the ST88-14 and STS-26T cell lines (Supplemental Figure 10A, 
B). 
In line with this set of targets, GSEA analysis showed that several signature data 
sets associated with this pathway were significantly downregulated by HuR silencing 
(Figure 9A, B; Supplemental Table 5 and 6). RIP analysis showed that HuR associated 
with CTNNB1 mRNA, which encodes β-Catenin, as well as BCL9 mRNA, which we also 
identified as a target of HuR from our RIP-Chip analyses (Supplemental Table 2) (Figure 
9C). A functional role of b-Catenin in controlling MPNST cell growth and viability had 
already been shown using shRNA-mediated silencing of CTNNB1 (34). 
HuR silencing led to a notable reduction in the levels of β-CATENIN and BCL9 in 
ST88-14 (Figure 9D) and STS-26T cells (Supplemental Figure 10C), showing that HuR 
controlled protein production from these mRNAs. HuR depletion also significantly 
lowered the levels of the key downstream targets, including c-MYC, SOX9, AURKA and 
AURKB, further supporting a role for HuR in regulating Wnt/b-Catenin-mediated gene 
transcription. To confirm these results, we examined the capacity of ectopically 
expressing a degradation-resistant form of b-Catenin to abrogate the effects of HuR 
silencing in MPNST cells. We found that constitutive expression of the b-Catenin mutant 
partially blocked the effects of HuR silencing on downregulation of the downstream Wnt 
pathway targets in ST88-14 MPNST cells (Figure 9E). In line with this, although silencing 
HuR still reduced ATP levels and cell number in cells overexpressing the b-Catenin 
mutant, there was a significant recovery in these parameters when compared to HuR-
silenced cells expressing the empty vector plasmid (Figure 9F). Similar results were 
obtained in the sporadic MPNST STS-26T cell line (Supplemental Figure 10D, E).  
Conversely, attempts to rescue by overexpressing BCL9 using a lentiviral vector 
in HuR-silenced cells failed to affect MPNST growth (data not shown), suggesting that 
regulation of BCL9 is not central to the biological consequences elicited by HuR in 
MPNST cells. Our results above also show that a number of key oncogenic TFs, including 
c-MYC, SOX9 or E2Fs, were downregulated by HuR silencing. Similarly, here, we found 
no major effect on MPNST growth when the expression of these TFs was restored using 
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lentiviral overexpression constructs after HuR silencing (Supplemental Figures 11 and 
12).  
These data suggest that there is hierarchical prioritization for HuR function in 
MPNSTs: HuR primarily regulates the expression of key master regulators (e.g., b-
Catenin, YAP/TAZ), which in turn control the production of cell cycle proteins and TFs. 
 
HuR regulates a core transcriptional circuitry in MPNST cells by controlling expression 
of BRD proteins  
Deregulation of the epigenome has also emerged as an important component of 
the pathogenesis of MPNST. In particular, two recent studies pointed to a role of 
bromodomain (BRD) and extra-terminal domain (BET) proteins in the activation and 
maintenance of an aberrant transcriptional program (13,32). BET proteins (BRD2, BRD3 
and BRD4) bind to hyperacetylated lysines in promoter/enhancer regions, and 
subsequently recruit cofactors to control transcription of oncogenic drivers, such as MYC 
and E2F (42).  
In MPNST cells, a small-molecule inhibitor of the BET proteins, JQ1, blocks 
proliferation and can induce apoptosis in MPNST cells in vitro and in vivo, highlighting 
the importance of these proteins in MPNST pathogenesis(13,32). Using GSEA analysis, 
we found a striking enrichment of genes activated by JQ1 treatment in MPNST cells (13), 
and genes upregulated by HuR silencing in our dataset (Figure 10A). Furthermore, in line 
with our RIP-Chip analyses, where we found enrichment of BRD2 mRNA in HuR-bound 
fractions (Supplemental Table 2), we found that mRNAs encoding all 3 BET family 
members, BRD2, BRD3 and BRD4, were highly enriched in HuR fractions in RIP-qPCR 
analyses of MPNST cell lines (Figure 10B). HuR silencing strongly reduced all three BET 
proteins in both the ST88-14 and STS-26T cell lines, suggesting a role for HuR in 
promoting the stability and/or translation of the corresponding mRNAs (Figure 10C and 
Supplemental Figure 13A). A functional role of BRD4 in controlling cell growth and 
viability in MPNST cells had already been shown using shRNA-mediated silencing 
(13,32). Here, we found that silencing BRD2 using two distinct BRD2-specific shRNAs also 
led to a reduction in cell growth and viability (Supplemental Figure 13B–D), underscoring 
the importance of this transcriptional regulator in MPNST. 
 Key recent studies have shown that JQ1 treatment in melanoma and multiple 
myeloma cells depletes BRD2 and BRD4 from promoter and enhancer regions of the 
genome and this was associated with the disruption of transcriptional programs in these 
cells (43,44). To gain mechanistic insight into the role of HuR in mediating the function 
of BET proteins in MPNST cells, we investigated changes in BET occupancy on a genome 
scale by ChIP-Seq in ST88-14 cells after HuR silencing. We found that HuR silencing 
significantly reduced genome-wide BRD2, BRD3 and BRD4 occupancy by ~60%, ~50% 
and ~45% respectively (Figure 10D). 
Next, to examine the functional effects of the BETs occupancy on transcriptional 
regulation, we generated a chromatin landscape in ST88-14 cells using H3K4me3 to 
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identify promoters, H3K4me1 to identify enhancers, and H3K27ac to identify active 
promoter/enhancer regions. Using this information, we performed network analysis to 
generate a network of transcriptional regulators that are targets of BRD proteins and 
regulated by HuR expression. In brief, we identified BRD-bound epigenetically active 
(active promoters and enhancers) and differentially regulated TFs in control and HuR-
silenced cells (Figure 10E). It is apparent from this analysis that there is a considerable 
number of transcriptional regulators in MPNST cells that are associated with BRD 
proteins and that control key processes, such as proliferation. Importantly, we found 
that a substantial proportion of these transcriptional regulators were especially 
sensitive to HuR inhibition, which depleted BRD proteins from their promoter/enhancer 
regions and downregulated their expression (red circles). Thus, GSEA analysis of BRD-
bound transcriptional regulators demonstrated a significant enrichment of genes 
activated in control cells and repressed by HuR silencing (Figure 10F). Gene enrichment 
analysis by ToppGene suite (45) identified these repressed regulators as being 
overrepresented in different oncogenic pathways, including E2F and MYC TF networks, 
proliferation and TP53-regulated pathways, and for different cancers (Figure 10G, H). 
Collectively, these data demonstrate that BRD proteins are enriched at 
promoter/enhancer regions of key transcriptional regulators in MPNST cells, and that a 
reduction in their levels and genome occupancy by HuR silencing suppresses this 
oncogenic transcriptional circuitry. 
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DISCUSSION 
Cancer arises from multiple genetic lesions that lead to aberrant gene expression 
programs, which are increasingly being recognised as fundamental for the acquisition, 
development and maintenance of cancer phenotypes. Compelling recent evidence 
shows that cancer cells can develop absolute dependencies on discrete molecular 
regulators – out of the thousands of human proteins that contribute to control of gene 
expression – that drive these dysregulated transcriptional programs. There is nowadays 
an intense search for these key regulators through focussed mechanistic studies, since 
they represent attractive targets for effective and enduring therapies in cancer (9,10). 
In this study, we present evidence that MPNST cells exhibit an exceptional 
reliance on the RNA-binding protein HuR for their abilities to survive, proliferate and 
disseminate. HuR inhibition prevented the formation of tumours in xenograft models, 
and even induced a striking regression of tumour volume in established tumours. 
Furthermore, HuR strongly promoted the metastatic capacity of MPNST cells, one of the 
worst prognostic features of this cancer. We propose that HuR-regulated 
transcriptomes promotes the survival and adaptation strategies that allow the 
disseminated cancer cells to survive in the circulation, migrate to, extravasate and thrive 
in incompatible foreign microenvironments of distant tissues. Consistent with these 
results, we found that HuR regulated essential biological capabilities of MPNST cells, 
including cell cycle progression and sustained proliferation, resisting cell death in stress 
conditions and enabling replicative immortality. Notably, the functional consequences 
of HuR inhibition was largely comparable in a representative panel of 4 MPNST cell lines, 
obtained from patients with different NF1 status, even though these exhibit 
heterogeneous cellular growth rates and alterations in expression of a number of cell 
cycle proteins (24). This lack of major differences, functionally or mechanistically, 
between NF1-derived and sporadic MPNSTs after HuR silencing support the view that 
relatively similar molecular mechanisms are involved in the pathogenesis of MPNST, and 
that HuR can be a broad target for MPNSTs, irrespective of NF1 status (1).  
Mechanistically, our RIP-Chip and transcriptomics data showed a global 
dysregulation of several signalling pathways and molecular regulators in these cancer 
cells, including the HIPPO-YAP/TAZ, PI3K/AKT/mTOR, RAS/RAF-MEK-ERK and Wnt/b-
Catenin pathways and bromodomain regulation of gene transcription, while our focused 
analyses revealed that regulation by HuR of specific components of these pathways 
likely led to the aberrant signalling. Several of these pathways, including WNT/b-
Catenin, seem to be specific to MPNSTs, since we find that HuR cannot regulate them in 
normal Schwann cells (data not shown). We posit that this capacity of HuR to 
simultaneously control several essential molecular regulators that operate in these 
cancer cells explains in large part the striking effects of HuR inhibition in MPNST cells. 
All these pathways have been shown to contribute to MPNST pathogenesis in seminal 
studies from several laboratories using various genetically engineered mouse models or 
culture systems (1,2,6,13,32-34,46). However, genetic or pharmacological inhibition of 
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these targets individually have, in general, been modestly effective and largely 
cytostatic. Instead, concurrent targeting of different pathways has proved more potent. 
Thus, combined inhibition of YAP/TAZ and PDGFR signalling activity (6), BRD proteins 
and MEK activity (13), or the mTOR and Wnt/b-Catenin pathways (34) are strongly 
synergistic in blocking tumour growth, and can even induce apoptosis. 
These observations strongly support the view that parallel and redundant 
pathways control the oncogenic traits in MPNST cells, a phenomenon that has been 
associated with the emergence of therapeutic resistance in cancer cells (10,21). This is 
particularly true for targeted therapies against kinase-mediated signalling cascades, 
which are organized in a linear and hierarchical manner, with different receptor tyrosine 
kinases at the top, activating a reduced number of kinase signalling cascades, including 
RAS-RAF-ERK, PI3K-AKT and JAK-STAT that operate in parallel but which can crosstalk 
with one another (10). This linear and redundant architecture facilitates bypassing of a 
signalling pathway after its inhibition for another, thus blocking the therapeutic effects 
of the drugs. This paradigm is also consistent with the disappointingly poor results 
obtained from Phase I and Phase II clinical trials from targeting individual components 
of kinase cascades in MPNST patients. Because of the superior results obtained from 
additive effects of cotargeting multiple pathways, current clinical trials are more focused 
on combination drug therapy (1,25). Our results strongly argue that targeting HuR could 
be as equally effective as the combined treatments, as we find that HuR inhibition 
potently suppresses several of the oncogenic signals in MPNSTs, leading to the profound 
cytostatic and cytotoxic effects on tumour growth, as well as on their metastatic 
capacity.  
Strikingly, we find that targeting HuR can both prevent the formation of tumours 
and metastatic nodules, as well as lead to shrinkage of fully established tumours and 
metastases. Thus, therapeutic intervention could be equally effective in newly 
diagnosed or recurrent tumours, which has particularly appealing translational 
importance, since timing of intervention and stage of disease has been raised as a 
possibility for negative clinical trials in MPNSTs. However, even though our promising 
data on pharmacological inhibition of HuR could represent a viable therapy for patients 
with MPNST, it is still unclear whether the preclinical efficacy observed in this study 
using cell lines and mice can be translated to the clinic. Whether HuR is a valid 
therapeutic target in MPNST warrants direct investigation.  
Our ChIP-Seq data reveal a large network of transcriptional regulators operating 
in MPNST cells that are associated with key biological functions. Notably, we find that 
this network is highly sensitive to levels of HuR that regulate expression of these 
regulators via regulation of BRD protein levels, and/or signalling pathways. An essential 
role for BRD proteins in regulating gene expression has also been shown in several 
malignancies, including MPNST, and interestingly, we find that HuR silencing in MPNST 
phenocopies to a large extent treatment with the BET inhibitor JQ1, at least in terms of 
gene expression profiles. In addition, the displacement of BRD proteins on 
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promoter/enhancer regions of active cancer-related genes by JQ1 in haematological 
malignancies and melanoma (42-44) is similar to the reduced promoter/enhancer 
occupancy on transcriptional regulators in MPNSTs we found after HuR silencing. Thus, 
our data suggest that the dysregulation of the transcriptional program in MPNST by HuR 
silencing, could be in large part mediated by the influence of HuR on the MPNST 
transcriptional network. 
Remarkably, we found that HuR depletion led to strong suppression of MYC and 
E2Fs levels that was accompanied by a highly significant reduction in the abundance of 
MYC- and E2F-transcribed gene sets, pointing to a general suppression of transcription 
at E2F- and MYC-driven targets by HuR inhibition. These proto-oncogenic TFs are among 
the most important drivers of tumorigenesis, as they regulate cell growth, proliferation, 
apoptosis and metabolic pathways (22,23), and represent some of the important targets 
for cancer therapy, although efforts to directly target these TFs have proved 
unsuccessful so far (9). Our work could thus have far-reaching implications for cancer 
therapy, since it suggests an alternative strategy to effectively target these TFs. MYC 
regulation also represents one of the best examples of the “multifunctional” capacity of 
HuR in driving expression of particular oncoproteins. MYC levels are regulated by major 
growth-regulatory and oncogenic signalling pathways, including the Wnt/b-Catenin, 
JAK-STAT and Notch pathways that induce MYC transcription and mTOR pathway that 
increases the efficiency of MYC mRNA translation, together with function of the PI3K 
and RAS signalling, and AURKA/B in increasing the stability of MYC protein (22,47). The 
striking downregulation of MYC levels in MPNST cells by HuR inhibition could potentially 
be mediated by a combinatorial action at several of these nodes of regulation, that are 
themselves under strong HuR influence. Similarly, E2F levels/function in MPNST cells 
could be determined by HuR by affecting multiple regulatory mechanisms, including 
Cyclin-CDK expression, RB phosphorylation and E2Fs transcription/translation. 
RBPs play a central role in regulation of gene expression, and thus it is not 
surprising that their dysregulation has been linked to several human diseases, including 
neurological disorders and cancer (48,49). These dynamic regulators can bind to and 
regulate thousands of functionally related genes, regulating every hallmark of cancer 
cells. Recent detailed studies have shown that RBPs are rapidly emerging as key 
oncogenic drivers in a variety of malignancies (48,50-53). In this study, we show the RBP 
HuR has pleiotropic functions in MPNST, driving tumour growth and metastasis by, quite 
strikingly, influencing almost all key signalling pathways and regulators discovered in 
MPNSTs so far, including the PI3K/AKT/mTOR, RAS-RAF-MEK-ERK, WNT/b-Catenin and 
HIPPO-YAP/TAZ pathways, and transcriptional regulators that include SOX9, AURKA/B, 
BRD proteins, as well as the proto-oncogenic TFs MYC and E2Fs. Over 1500 RBPs have 
been described and several of them are dysregulated in MPNSTs (data not shown). It 
would be interesting to examine their biological and mechanistic functions in MPNSTs, 
and whether they have broad functions similar to HuR or regulate distinct pathways 
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This function of HuR in establishing the highly intricate regulatory networks 
operating in MPNSTs to coordinate multiple cancer hallmark traits supports a “master” 
regulatory function for HuR in MPNST. Thus, by elevating HuR levels, MPNST cells have 
elaborated an adaptive mechanism to amplify and regulate key oncogenic signals and 
modulate transcriptional programs to confer a competitive advantage to these cancer 
cells, promoting MPNST growth and metastatic spread (graphical abstract).  
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MATERIALS AND METHODS 
 
Cell culture 
Human MPNST cell lines S-462, STS-26T, ST88-14 and 90-8, and immortalized normal 
human Schwann cell line (iHSCl2) were obtained from Nancy Ratner (Cincinnati 
Children’s Hospital Medical Centre)(24,34). Immortalized plexiform neurofibroma-
derived Schwann cells (ipNFSC) was purchased from ATCC (ATCC® CRL3390™). The cells 
were maintained in Dulbecco’s modified Eagle Medium (DMEM) (Thermo Fisher 
Scientific) supplemented with 10% (v/v) fetal bovine serum (FBS) (Thermo Fisher 
Scientific) and 1% (v/v) antibiotic/antimycotic (Thermo Fisher Scientific) under standard 
conditions of culture in 37 °C and 5% CO2.  
Human Schwann cells were isolated from the sural nerves of donors with informed 
consent (see below). Withdrawn nerves were stripped of their epineurium and fascicles 
were separated from the remaining interfascicular epineurium. Fascicles were cut into 
2-mm-long pieces and incubated in humidified conditions and 10% CO2 for 7-14 days in 
DMEM (Gibco) with 10% FBS (Sigma), 500 U/mL penicillin/streptomycin (Gibco) and 2.5 
mg/mL Amphotericin (Gibco). Fascicles were then digested in DMEM with 10% FBS; 500 
U/mL penicillin/streptomycin; 0.8 U/mL dispase grade I (Sigma) and collagenase type 1A 
160 U/mL (Sigma). The resulting Schwann cells were then amplified on plates coated 
with 0.1 mg/mL Poly-L-lysine in DMEM with 20% FBS; 100 U/mL penicillin/streptomycin; 
0.5 mM Forskolin (Sigma); 2.5 mg/mL Amphotericin 2.5 mg/mL; 2.5 mg/ml Insulin 
(Sigma); 10 nM b1-heregulin (Sigma) and 0.5 mM IBMX (Sigma). Amplified Schwann cells 
were plated in DMEM with 10% FBS in the absence of b1-heregulin for at least 24 hours 
before analysis. 
 
Lentivirus preparation and infection of MPNST cells 
Lentiviral particles (Supplemental Table 7) were produced in HEK293FT cells. For single-
infection experiments, MPNST cells were incubated with different lentiviral particles 
together with 8 µg/mL polybrene (Merck) for enhancing infection efficiency. Selection 
of infected cells was started 48 h post-infection with puromycin (4 µg/mL) for 2 days in 
supplemented growth medium or with geneticin (G418 sulfate) (Thermo Fisher 
Scientific) at 50 µg/mL for 5 days in growth medium without antibiotic/antimycotic. For 
the inducible knockdown plasmids, after infection and selection, cell lines were treated 
with 0.5 µg/ml doxycycline every 24 h for 3 days. Infection efficacy was tested by 
western blot and RT-qPCR analyses. For rescue experiments, cells were first infected 
with control or b-Catenin overexpressing plasmids and selected with puromycin, and 
then further infected with shHuR#3 lentiviral particles followed by selection with 
geneticin, as above. After infection and selection, MPNST cells were replated at specific 
densities for the different functional assays. All assays were conducted in triplicate, with 
at least 3 independent experiments performed for each assay. 
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Small molecule HuR inhibitors 
For culture studies, MPNST cell lines were treated with the following small molecule HuR 
inhibitors for 48h: (a) MS-444 (29), obtained from Philipp Krastel (Novartis Institutes for 
Biomedical Research), reconstituted in DMSO and used at a final concentration of 10 
µM. (b) Pyrvinium pamoate (Sigma), reconstituted in DMSO and used at a final 
concentration of 2 µM. (c) Tanshinone mimic 6N (TM-6N) (31), obtained from 
Alessandro Provenzani (University of Trento), reconstituted in DMSO and used at a final 
concentration of 10 µM. 0.1% DMSO was used in control cultures. 
For in vivo xenograft studies, 1 X 106 STS-26T cells mixed in 1:4 PBS:Matrigel were 
injected subcutaneously in the left and right back flanks of mice respectively under 
standard procedures and tumours allowed to grow up to 100 mm3 average volume, as 
described above. The mice then received intraperitoneal (IP) injections of MS-444 (25 
mg/kg) dissolved in PBS/5% N-Methyl Pyrrolidine (NMP) (Sigma-Aldrich) or vehicle 
control every 48 hr for a further 10 days.  
For lung metastasis studies, 1 X 106 STS-26T cells were injected in the lateral tail vein of 
mice, and left for 2 weeks to allow basal formation of lung metastases, as described 
above. The mice then received IP injections of MS-444 (25 mg/kg) dissolved in PBS/5% 
N-Methyl Pyrrolidine (NMP) (Sigma-Aldrich) or vehicle control every 48 hr for a further 
2 weeks.  
 
Statistics 
All analyses were done using Microsoft Excel or GraphPad Prism 6.00 (San Diego 
California, www.graphpad.com). Data are shown in dot plots or histograms as mean ± 
SEM, p < 0.05 is deemed statistically significant. Statistical analysis was performed by 
two-tailed unpaired Student’s t tests, Mann Whitney U test, one-way ANOVA with post 
hoc analysis by Tukey’s multiple comparison test, or Two-way ANOVA with Tukey’s 
multiple comparisons test, or as indicated. Quantifications were performed from a 
minimum of three experimental groups. 
 
Study Approval 
Animal Studies: Xenograft or experimental lung metastasis experiments were carried 
out following the ethical guidelines established by the Biosafety and Welfare Committee 
(BAWC) at CIC bioGUNE following the recommendations from AAALAC. 
Human Studies: Patient samples were obtained in accordance with the ethical standards 
of the institutional and/or national research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical standard:  
(1) the Stanmore Musculoskeletal Biobank, a satellite of the UCL/UCLH Biobank (HTA 
Licence Number 12055), which was approved by the National Research Ethics 
Committee (reference 15/YH/0311). This specific study was approved by the NREC-
approved UCL/UCLH Biobank Ethical Review Committee (reference EC17.14).  
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(2) Peripheral nerves for Schwann cell culture were retrieved from donors after consent 
under NHS Blood and Transplant (NHSBT) research study entitled ‘Collection of 
peripheral nerves for control cells for brain tumour treatment research’, NHSBT study 
(61). Full research project title was ‘Identifying and validating molecular targets in low 
grade brain tumours; REC number: 14/SW/0119; IRAS reference: 153351. 
 
Accession Codes 
All the microarray, RNA-seq and ChIP-Seq data are deposited in the NCBI Gene 
Expression Omnibus (GEO) with the accession number GSE120687. 
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